Adtran launches new FSP 3000 OLS to unlock the coherent optical edge
25.5.2023 15:00:00 EEST | Business Wire | Press release
Adtran today launched its FSP 3000 Edge OLS, an open line system designed for the new generation of coherent edge access, aggregation and metro networks. It enables operators to efficiently address soaring bandwidth demand from mobile, broadband and enterprise applications by leveraging the latest coherent pluggable technology in this cost-sensitive part of the network. The FSP 3000 Edge OLS has been specifically engineered for the use of coherent transmission at the optical edge, including the recently introduced Coherent 100ZR, as well as 400ZR optics. By utilizing power-optimized wavelength broadcasting technology and a gridless architecture, the solution enables a simple and affordable optical layer with compact and flexible nodes that can transport any coherent signal and baud rate.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005466/en/
Adtran’s FSP 3000 Edge OLS will help operators deploy coherent optical edge networks in the most effective way possible. (Graphic: Business Wire)
“At OFC, we showcased our world-first QSFP28 Coherent 100ZR, bringing robust, efficient and simple coherent technology to the edge of the network. Now we’re complementing this innovative transceiver with an OLS optimized for the cost-efficient transport of coherent technology at the optical edge. Providing maximum performance, it meets all critical demands of edge aggregation networks, including scalability, compact design, low power consumption, operational simplicity and extended temperature operation for outdoor deployment,” said Christoph Glingener, CTO at Adtran. “Our pioneering work at the network edge is creating whole new opportunities for service providers.”
The Adtran FSP 3000 Edge OLS is an open line system engineered to help operators roll out coherent optical edge networks in the most cost-effective and flexible way possible. With ZR-optimized technology for minimal insertion loss, the new OLS enables the use of ZR coherent optics at the optical edge in multiple use cases, including linear, hub-and-spoke or tree topologies. With its modular design, it empowers users to mix and match elements to create a solution that meets their exact needs. What’s more, the Adtran FSP 3000 Edge OLS facilitates the development of a compact and efficient optical layer with low-power nodes that require minimal space and can function in an extended temperature range. This enables deployment in outdoor environments, such as street cabinets.
“Our FSP 3000 Edge OLS offers a major boost to operators looking for an affordable way to tackle relentless growth in data traffic. Low-cost yet highly flexible, it can scale to transparently accommodate any line speed or baud rate. Now there’s a clear route to deploying an optical layer that leverages coherent transport technology, including 100ZR and 400ZR optics, and meets the stringent requirements of the new optical edge,” commented Henning Hinderthür, VP of product line management, Optical Networks at Adtran. “Our FSP 3000 Edge OLS harnesses advanced wavelength broadcast technology for new levels of power and cost efficiency. It’s also ready to be deployed anywhere from central offices to street furniture.”
Further details on Adtran’s FSP 3000 Edge OLS are available in these slides.
A supporting product video is available to watch.
A solution brief can also be downloaded.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of ADVA. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005466/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
